- April 28, 2013
Heptares achieves all research milestones and receives milestone payment from GPCR drug discovery agreement with Takeda
- March 18, 2013
Heptares StaRs® enable ‘reverse pharmacology’ approach to accelerate GPCR-focused drug discovery
- December 17, 2012
Naurex Completes $38 Million Series B Financing
- December 6, 2012
Redwood Bioscience Announces The Appointment of Gordon Foulkes, PhD as Executive Chairman
- November 9, 2012
ArmaGen Technologies, Inc. Announces $17 Million Series A Financing
- November 13, 2012
Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed
Combination of Namenda XR® and Donepezil for Alzheimer's Disease
- November 6, 2012
Takeda to Acquire Envoy Therapeutics, Inc.
- November 5, 2012
Domainex announces that compounds from its IKKepsilon programme have activity against the IL-17 signaling pathway
- October 15, 2012
Fate Therapeutics Appoints Christian Weyer as President and Chief Executive Officer
- July 16, 2012
Juventas Therapeutics announces it has closed a $22.2 million Series B financing
- May 7, 2012
Michael J. Fox Foundation Expands Funding to Envoy
- December 14, 2011
Fate Therapeutics announces the appointment of William H. Rastetter as Chairman and Interim CEO
- November 7, 2011
Naurex's Novel Antidepressant GLYX-13 Recognized As One of Windhover's 2011 Top 10 Neuroscience Projects to Watch
- June 27, 2011
Redwood Bioscience Secures Funding for Optimized Conjugate Drug Development
- May 11, 2011
Naurex Completes $18 Million Series A Financing
Takeda Ventures, Inc.
Catching the Next Wave in Health Care Innovation
Takeda Ventures, Inc. (TVI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC) a world-class pharmaceutical company and the largest in Japan. TVI (formerly Takeda Research Investment, Inc.), was founded in 2001 with the vision to extend Takeda’s reach into the Global scientific community and forge strategic relationships that complement and expand internal R&D capabilities. The change in name to Takeda Ventures, Inc. in 2011 reflects an intention to further leverage TVI’s venture networks to engage with new scientific and business avenues for Takeda, using strategic venturing to enable staged-entry into new spaces in a fully-informed manner. Our aim is to encourage and support therapeutic innovation in the biopharmaceutical sector, as well as academic centers of excellence, through early stage capital investment and the provision of access to the resources of a multinational pharmaceutical company.